Texas Health Resources

adtrk.tw

At Texas Health Resources, our mission is to improve the health of the people in the communities we serve. We are one of the largest faith-based, nonprofit health systems in the United States with a team of more than 23,000 employees of wholly owned/operated facilities plus 2,200 employees of consolidated joint ventures in the greater Dallas Fort Worth area. Our career growth and professional development opportunities are top-notch and our benefits are equally outstanding.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

EPIGENETIC CHANGES MAKE BREAST CANCER CELLS DRUG RESISTANT

LabRoots | January 20, 2020

news image

Changes in the epigenetics - the modifiable chemical tags that can change the genome and gene expression - of breast cancer cells can make them resistant to drugs that are targeting them. This seems to happen to ER+ breast cancer cells, which make up around two of every three cases of breast cancer. This type of cancer can become resistant to the hormonal therapy used to treat it. Breast cancer relapse could be reduced, researchers suggested, if these epigenetic changes can be reversed. Re...

Read More

INTRAVACC RECEIVES US NIH/NIAID CONTRACT TO DEVELOP ENTEROVIRUS D68 VACCINE

Intravacc | September 08, 2020

news image

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract with base and options that may total US$9.4 million from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68). EV D68 is a respiratory virus that can cause childhood paralysis, Acute Flaccid Myelitis (...

Read More

Pharmacy Market

XERIS BIOPHARMA ANNOUNCES RESEARCH EVALUATION COLLABORATION AND OPTION AGREEMENT WITH REGENERON FOR XERIJECT™

businesswire | April 03, 2023

news image

Xeris Biopharma Holdings, Inc. a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, today announced that it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals, Inc. Under the terms of the agreement, Xeris will use its proprietary drug-formulation platform, XeriJect™, to develop ultra-highly concentrated, ...

Read More

Business Insights

DAEWOONG PHARMACEUTICAL AND HANALL BIOPHARMA INVEST IN TURN BIOTECHNOLOGIES TO EXPAND GROWTH INITIATIVE

Daewoong Pharmaceutical and HanAll Biopharma | April 12, 2022

news image

Daewoong Pharmaceutical and HanAll Biopharma announced expansion of their open collaboration strategy by investing in Turn Biotechnologies, a Silicon Valley based company focused on developing novel mRNA medicines. The companies are supporting Turn Bio's continued development of a high-potential platform and are considering future long-term collaborations. Turn Bio is a pre-clinical-stage biopharmaceutical company focused on cellular repair via epigenetic reprogramming of cell...

Read More
news image

EPIGENETIC CHANGES MAKE BREAST CANCER CELLS DRUG RESISTANT

LabRoots | January 20, 2020

Changes in the epigenetics - the modifiable chemical tags that can change the genome and gene expression - of breast cancer cells can make them resistant to drugs that are targeting them. This seems to happen to ER+ breast cancer cells, which make up around two of every three cases of breast cancer. This type of cancer can become resistant to the hormonal therapy used to treat it. Breast cancer relapse could be reduced, researchers suggested, if these epigenetic changes can be reversed. Re...

Read More
news image

INTRAVACC RECEIVES US NIH/NIAID CONTRACT TO DEVELOP ENTEROVIRUS D68 VACCINE

Intravacc | September 08, 2020

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract with base and options that may total US$9.4 million from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68). EV D68 is a respiratory virus that can cause childhood paralysis, Acute Flaccid Myelitis (...

Read More
news image

Pharmacy Market

XERIS BIOPHARMA ANNOUNCES RESEARCH EVALUATION COLLABORATION AND OPTION AGREEMENT WITH REGENERON FOR XERIJECT™

businesswire | April 03, 2023

Xeris Biopharma Holdings, Inc. a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, today announced that it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals, Inc. Under the terms of the agreement, Xeris will use its proprietary drug-formulation platform, XeriJect™, to develop ultra-highly concentrated, ...

Read More
news image

Business Insights

DAEWOONG PHARMACEUTICAL AND HANALL BIOPHARMA INVEST IN TURN BIOTECHNOLOGIES TO EXPAND GROWTH INITIATIVE

Daewoong Pharmaceutical and HanAll Biopharma | April 12, 2022

Daewoong Pharmaceutical and HanAll Biopharma announced expansion of their open collaboration strategy by investing in Turn Biotechnologies, a Silicon Valley based company focused on developing novel mRNA medicines. The companies are supporting Turn Bio's continued development of a high-potential platform and are considering future long-term collaborations. Turn Bio is a pre-clinical-stage biopharmaceutical company focused on cellular repair via epigenetic reprogramming of cell...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us